Transdermal scopolamine indications

Transdermal scopolamine has current FDA indication only for the prevention of nausea and vomiting associated with motion sickness and recovery from anesthesia and surgery in adults. There is currently no FDA approval for use in the pediatric setting. A single 1.5 mg transdermal scopolamine patch should only be applied to the hairless area of the skin over-lying the mastoid process. Only one patch should be worn at any time. The patch should not be cut or altered in any way as this will disrupt the delivery process. 

The answer is e. (Hardmanr p 930.) All the drugs listed in the question are used as antiemetics. Chlorpromazine is a general antiemetic, used orally, rectally, or by injection for the control of nausea and vomiting that is caused by conditions that are not necessarily defined. Ondansetron is indicated in the oral or intravenous route for the prevention of nausea and vomiting caused by cancer chemotherapy Diphenhydramine and dimen-hydrinate are used orally for the active and prophylactic treatment of motion sickness. Scopolamine is a transdermal preparation used in the prevention of motion sickness. The drug is incorporated into a bandage-like... 

Furthermore, central-acting antimuscarinic drug are effective in the treatment of motion sickness. In this indication the alkaloid scopolamine has been shown to be effective. It can be applied orally, intra venously or via a transdermal therapeutic system. 

Transdermal administration can avoid first-pass metabolism as well as provide a large surface area for continuous-controlled administration of drugs with short biological half-lives and narrow therapeutical indices. The route has been used for nitroglycerin ointments, and transdermal therapeutical systems (patches) have been developed for scopolamine, nitroglycerin, clonidine, estradiol, and nicotine. 

The female client tells the clinic nurse that she gets carsick every time the family goes on a vacation and the health-care provider prescribed the anticholinergic scopolamine (Transderm Scop). Which statement indicates the client understands the medication teaching ... 

The present Transdermal Therapeutic System-scopolamine is 2.5 cm in area, and its strength is specified by its temporal pattern of drug release 200 yg priming dose, 10 Vig/hr for 72 hours. Results of large scale clinical studies have indicated that the system is a safe and effec-... 

---